Prognostic factors in patients with intrahepatic cholangiocarcinoma.
Intrahepatic cholangiocarcinoma
Surgery
Survival
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 Aug 2024
17 Aug 2024
Historique:
received:
24
04
2024
accepted:
13
08
2024
medline:
18
8
2024
pubmed:
18
8
2024
entrez:
17
8
2024
Statut:
epublish
Résumé
Intrahepatic cholangiocarcinoma (ICC) is the second commonly-seen liver malignancy and one of the most fatal cancers in Taiwan. Survival after diagnosis of ICC remains poor. This study aimed to investigate the survival and prognostic factors in patients with ICC. All patients with newly diagnosed ICC during 2004 to 2018 were identified from a national cancer database and followed until December 2020. Estimates of overall survival (OS) were conducted using the Kaplan-Meier method and Cox proportional hazards model. Hazard ratios with 95% confidence intervals were calculated. Initially, 7940 patients with ICC disease (stage IV: 55.6%, 4418/7940) were eligible for this study. Only 32.3% (2563/7940) patients with ICC underwent liver resection. After Propensity score matching, 969 pairs (N = 1938) of patients were matched and selected (mean age 62.8 ± 11.0 years, 53.1% were male, 29.7% had cirrhosis). The median follow-up time was 80.0 months (range 25-201 months). The 3-, 5-year OS rates were 44.0%, 36.4% in the surgical group and 26.0%, 23.7% in the non-surgical group, respectively. Surgery, young patients (≤ 54 years), small tumor size, no vascular invasion and chemotherapy were associated with better OS in patients with stages I-III disease. Surgery benefit was maximum in stage I disease followed by stage II. In patients with stage IV disease, factors such as surgery, young patients (≤ 64 years), single tumor, and no vascular invasion were associated with better OS. Chemotherapy was insignificantly associated with better OS. Long-term survival in patients with ICC is very poor. Compared to non-surgical patients, surgery conveys approximately 18% and 12% better OS rates at 3-year and 5-year, respectively. Early detection and surgical intervention may improve OS substantially in patients with ICC.
Identifiants
pubmed: 39154139
doi: 10.1038/s41598-024-70124-z
pii: 10.1038/s41598-024-70124-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19084Informations de copyright
© 2024. The Author(s).
Références
Guglielmi, A. et al. Intrahepatic cholangiocarcinoma: Prognostic factors after surgical resection. World J Surg. 33, 1247–1254. https://doi.org/10.1007/s00268-009-9970-0 (2009).
doi: 10.1007/s00268-009-9970-0
pubmed: 19294467
Shaib, Y. H. et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study. Gastroenterology. 128, 620–626. https://doi.org/10.1053/j.gastro.2004.12.048 (2005).
doi: 10.1053/j.gastro.2004.12.048
pubmed: 15765398
Wu, Z. F. et al. Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma. World J Gastroenterol. 21, 935–943. https://doi.org/10.3748/wjg.v21.i3.935 (2015).
doi: 10.3748/wjg.v21.i3.935
pubmed: 25624728
pmcid: 4299347
Cardinale, V. et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol. 2, 407–416. https://doi.org/10.4251/wjgo.v2.i11.407 (2010).
doi: 10.4251/wjgo.v2.i11.407
pubmed: 21160904
pmcid: 3000454
Suarez-Munoz, M. A. et al. Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol. 5, 132–138. https://doi.org/10.4251/wjgo.v5.i7.132 (2013).
doi: 10.4251/wjgo.v5.i7.132
pubmed: 23919107
pmcid: 3731526
Blechacz, B. R. & Gores, G. J. Cholangiocarcinoma. Clin Liver Dis. 12, 131–150. https://doi.org/10.1016/j.cld.2007.11.003 (2008).
doi: 10.1016/j.cld.2007.11.003
pubmed: 18242501
Anderson, C. D., Pinson, C. W., Berlin, J. & Chari, R. S. Diagnosis and treatment of cholangiocarcinoma. Oncologist. 9, 43–57. https://doi.org/10.1634/theoncologist.9-1-43 (2004).
doi: 10.1634/theoncologist.9-1-43
pubmed: 14755014
Hong, J. C. et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 146, 683–689. https://doi.org/10.1001/archsurg.2011.116 (2011).
doi: 10.1001/archsurg.2011.116
pubmed: 21690444
Singh, M. K. & Facciuto, M. E. Current management of cholangiocarcinoma. Mt Sinai J Med. 79, 232–245. https://doi.org/10.1002/msj.21298 (2012).
doi: 10.1002/msj.21298
pubmed: 22499494
Aljiffry, M. et al. Evidence-based approach to cholangiocarcinoma: A systematic review of the current literature. J Am Coll Surg. 208, 134–147. https://doi.org/10.1016/j.jamcollsurg.2008.09.007 (2009).
doi: 10.1016/j.jamcollsurg.2008.09.007
pubmed: 19228515
Nakagohri, T. et al. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg. 32, 2675–2680. https://doi.org/10.1007/s00268-008-9778-3 (2008).
doi: 10.1007/s00268-008-9778-3
pubmed: 18843437
Chang, Y. J., Chung, K. P., Chang, Y. J. & Chen, L. J. Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas. Br J Surg. 103, 1513–1520. https://doi.org/10.1002/bjs.10196 (2016).
doi: 10.1002/bjs.10196
pubmed: 27550624
Wu, C. Y. et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 308, 1906–1914. https://doi.org/10.1001/2012.jama.11975 (2012).
doi: 10.1001/2012.jama.11975
pubmed: 23162861
Chang, Y. J. et al. Application of propensity score model to examine the prognostic significance of lymph node number as a care quality indicator. Surg Oncol. 21, e75-85. https://doi.org/10.1016/j.suronc.2011.12.003 (2012).
doi: 10.1016/j.suronc.2011.12.003
pubmed: 22221938
Kudo, M. et al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 46, 372–390. https://doi.org/10.1111/hepr.12697 (2016).
doi: 10.1111/hepr.12697
pubmed: 26970231
Lubezky, N. et al. Surgical treatment of intrahepatic cholangiocarcinoma in the USA. J Hepatobiliary Pancreat Sci. 22, 124–130. https://doi.org/10.1002/jhbp.157 (2014).
doi: 10.1002/jhbp.157
pubmed: 25187408
Javle, M. et al. Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017. Oncologist. 27, 874–883. https://doi.org/10.1093/oncolo/oyac150 (2022).
doi: 10.1093/oncolo/oyac150
pubmed: 35972334
pmcid: 9526482
Ikai, I. et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res. 40, 1043–1059. https://doi.org/10.1111/j.1872-034X.2010.00731.x (2010).
doi: 10.1111/j.1872-034X.2010.00731.x
pubmed: 34818831
Spolverato, G. et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?. Cancer. 121, 3998–4006. https://doi.org/10.1002/cncr.29619 (2015).
doi: 10.1002/cncr.29619
pubmed: 26264223
Yu, T. H. et al. Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: A population-based study. Sci Rep. 11, 3990. https://doi.org/10.1038/s41598-021-83149-5 (2021).
doi: 10.1038/s41598-021-83149-5
pubmed: 33597569
pmcid: 7889915
Ali, S. M. et al. Model to predict survival after surgical resection of intrahepatic cholangiocarcinoma: The Mayo Clinic experience. HPB (Oxford). 17, 244–250. https://doi.org/10.1111/hpb.12333 (2015).
doi: 10.1111/hpb.12333
pubmed: 25410716
Uenishi, T. et al. The long-term outcomes after curative resection for mass-forming intrahepatic cholangiocarcinoma associated with hepatitis C viral infection: A multicenter analysis by Osaka Hepatic Surgery Study Group. J Surg Oncol. 110, 176–181. https://doi.org/10.1002/jso.23611 (2014).
doi: 10.1002/jso.23611
pubmed: 24760391
Hyder, O. et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: An Eastern and Western experience. JAMA Surg. 149, 432–438. https://doi.org/10.1001/jamasurg.2013.5168 (2014).
doi: 10.1001/jamasurg.2013.5168
pubmed: 24599477
Spolverato, G. et al. Is hepatic resection for large or multifocal intrahepatic cholangiocarcinoma justified? Results from a multi-institutional collaboration. Ann Surg Oncol. 22, 2218–2225. https://doi.org/10.1245/s10434-014-4223-3 (2014).
doi: 10.1245/s10434-014-4223-3
pubmed: 25354576
pmcid: 4834710
Zhou, H. B. et al. Hepatitis B virus infection: A favorable prognostic factor for intrahepatic cholangiocarcinoma after resection. World J Gastroenterol. 17, 1292–1303. https://doi.org/10.3748/wjg.v17.i10.1292 (2011).
doi: 10.3748/wjg.v17.i10.1292
pubmed: 21455328
pmcid: 3068264
Zhou, H. B., Hu, J. Y. & Hu, H. P. Hepatitis B virus infection and intrahepatic cholangiocarcinoma. World J Gastroenterol. 20, 5721–5729. https://doi.org/10.3748/wjg.v20.i19.5721 (2014).
doi: 10.3748/wjg.v20.i19.5721
pubmed: 24914333
pmcid: 4024782
Lee, T. Y. et al. Effect of nucleos(t)ide analogue therapy on risk of intrahepatic cholangiocarcinoma in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 16, 947–954. https://doi.org/10.1016/j.cgh.2017.09.031 (2018).
doi: 10.1016/j.cgh.2017.09.031
pubmed: 28951229
Bektas, H. et al. Surgical treatment for intrahepatic cholangiocarcinoma in Europe: A single center experience. J Hepatobiliary Pancreat Sci. 22, 131–137. https://doi.org/10.1002/jhbp.158 (2014).
doi: 10.1002/jhbp.158
pubmed: 25159731
Miura, J. T. et al. Chemotherapy for surgically resected intrahepatic cholangiocarcinoma. Ann Surg Oncol. 22, 3716–3723. https://doi.org/10.1245/s10434-015-4501-8 (2015).
doi: 10.1245/s10434-015-4501-8
pubmed: 25777092
De, B. et al. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer. 128, 2529–2539. https://doi.org/10.1002/cncr.34223 (2022).
doi: 10.1002/cncr.34223
pubmed: 35417569
Weber, S. M. et al. Intrahepatic cholangiocarcinoma: Expert consensus statement. HPB (Oxford). 17, 669–680. https://doi.org/10.1111/hpb.12441 (2015).
doi: 10.1111/hpb.12441
pubmed: 26172134
pmcid: 4527852
Beal, E. W., Cloyd, J. M. & Pawlik, T. M. Surgical treatment of intrahepatic cholangiocarcinoma: Current and emerging principles. J Clin Med. 10, 104. https://doi.org/10.3390/jcm10010104 (2020).
doi: 10.3390/jcm10010104
pubmed: 33396821
pmcid: 7796337